地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:18372041646
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理SYnAbs品牌抗体。
SYnAbs公司针对免疫原性较差的化合物和复杂抗原进行开发,其抗体产品线范围包括:针对跨膜蛋白(GPCR、离子通道、转运蛋白)、类固醇、小分子、毒素、脂质和
多糖(针对真菌和细菌)的单克隆抗体。为了应对针对半抗原和膜蛋白产生创新单克隆抗体的挑战,SYnAbs公司开发了一整套技术,结合了:
(1)通过专有技术进行创新抗原设计SYnDNA载体、SYnCell同基因细胞系和特殊佐剂;
(2)专有大鼠LOU物种、野生型、敲除型和多种转基因物种(包括 ATX-Gx 转基因小鼠平台)的多物种免疫;
(3)独特的免疫策略打破免疫耐受并触发特定表位;
(4)稀有B细胞群的选择和分离。
部分单克隆抗体:
Rat anti-human CD2 Siplizumab (LO-CD2a/BTI-322)
Mouse anti-human chemokine receptor
Rat anti-Valproic acid hapten,Rat anti-galactomannan
IgG2b kappa rat anti-His tag (N-ter & C-ter)
IgG1 rat anti-human IgG4
IgG1 kappa rat anti-dinitrophenyl hapten
创新型一抗:
(1)高价值一抗针对复杂和小分子的一抗
(2)同型对照和不相关抗体(抗DNP)
大量二抗:SYnAbs公司为生物技术、制药和体外诊断公司提供大量二抗单克隆抗体目录(超过一百种二抗免疫球蛋白)。
< " data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理SYnAbs品牌抗体"> 艾美捷科技代理SYnAbs品牌抗体
艾美捷科技代理Exocell品牌。
Exocell公司是一家专注于糖尿病及其并发症研究相关的产品与服务的生物制品公司。Exocell公司由Margo Cohen于1988年创立,致力于开发与糖尿病及其并发症相关的诊断产品。随着公司的不断发展,Exocell迅速成为该领域的重要供应商,拥有15项专利和2000多项研究引用。目前,Exocell产品已成为Ethos Biosciences(Ott Scientific的一部分)的一部分,继续为全球的学术、生物技术和制药研究团队提供服务。
Exocell产品与服务包括:
(1)临床诊断产品:
Albuwell:用于检测微白蛋白尿,是早期糖尿病性肾功能紊乱的明确标志物。
Creatinine:用于检测尿中的肌酐。
Glycaben:用于监测糖化白蛋白(中期的控糖指标)。
Glycacor:用于检测糖化LDL(短期控糖指标及心血管疾病风险指标)。
Hemoglobin A1c参照标准:长期控糖指标。
(2)临床研发类检测试剂与试剂盒:
Apo B Test:用于检测人血浆中的apolipoprotein B。
Collagen IV H:用于检测样本中的IV型胶原。
hFibronectin ELISA试剂盒:用于检测人血浆中的fibronectin。
Nephrin ELISA试剂盒:用于检测尿液中的nephrin等。
(3)实验室研究相关产品:
Albuwell M:用于检测小鼠样本中的微白蛋白尿。
Nephrat II:用于检测大鼠样本中的微白蛋白尿。
Glyco-Albumin R:用于检测大鼠血清中的糖化白蛋白等。
(4)糖尿病及其并发症研究相关的试剂及标准参照品:
A717:抗糖化白蛋白单克隆抗体。
E85:抗糖化血红素的单克隆抗体。
ES12:抗糖化LDL的单克隆抗体等。

艾美捷科技代理InSCREENeX品牌全系列产品
InSCREENeX GmbH成立于2009年,位于德国布伦瑞克亥姆霍兹感染研究中心内,是一家专注于开发细胞筛选技术的德国生物技术公司,InSCREENeX生产用于药物开发的细胞系统。InSCREENeX在该领域拥有超过15年的哺乳动物细胞基因修饰专业知识,在此期间成功开发了SCREENflex和CI-SCREEN这两项高度创新的技术。
利用SCREENflex技术,可以根据客户需求创建稳定的重组哺乳动物细胞。这种方法具有以下优势:快速建立所需的测试系统、目标基因的稳定表达,以及能够以不同水平调控该基因的表达。SCREENflex 技术具有普适性,已成功应用于建立多种蛋白质类别,例如 GPCRs(G蛋白偶联受体)、离子通道、抗体和细胞因子。InSCREENeX公司的产品包括稳定表达细胞系、永生化细胞系以及细胞培养试剂。

▍InSCREENeX产品线
● 稳定表达细胞系:包括离子通道、GPCRs、整合素及其他受体的稳定过表达细胞系
| 品名 | 货号 | Target | Cell background |
| CHO-Nav1.8 | INS-SF-1003 | human Nav1.8 plus beta subunit 1 | CHO |
| CHO-Nav1.7 | INS-SF-1037 | human Nav1.7 | CHO |
| CHO-PD-L1 | INS-SF-1028 | human PD-L1 | CHO |
| CHO-EpCAM | INS-SF-1027 | human EpCAM | CHO |
| CHO-PDCD1 | INS-SF-1026 | human PDCD1 | CHO |
| CHO-BCMA | INS-SF-1025 | human BCMA | CHO |
| CHO-B7H3 | INS-SF-1019 | B7H3 | CHO |
| HEK293-CTLA4 | INS-SF-1014 | CTLA4 | HEK293 |
| CHO-CTLA4 | INS-SF-1013 | CTLA4 | CHO |
| HEK293-CXCR4 | INS-SF-1006 | CXCR4 | HEK293 |
| CHO-CXCR4 | INS-SF-1004-L | CXCR4 | CHO |
| CHO-CXCR4 | INS-SF-1004-MH | CXCR4 | CHO |
| HEK293-CXCR7 | INS-SF-1009 | CXCR7 | HEK293 |
| CHO-CXCR7 | INS-SF-1007-L | CXCR7 | CHO |
| CHO-CXCR7 | INS-SF-1007-MH | CXCR7 | CHO |
| HEK293-FOLR1 | INS-SF-1018 | FOLR1 | HEK293 |
| CHO-FOLR1 | INS-SF-1017 | FOLR1 | CHO |
| HEK293-HER2 | INS-SF-1012 | HER2 | HEK293 |
| CHO-HER2 | INS-SF-1010-MH | HER2 | CHO |
| CHO-HER2 | INS-SF-1010-H | HER2 | CHO |
| HEK293-TACD2 | INS-SF-1016 | TACD2 | HEK293 |
| CHO-TACD2 | INS-SF-1015 | TACD2 | CHO |
| HEK293-FAP | INS-SF-1001 | FAP | HEK293 |
| HEK293-CCR8 | INS-SF-1024 | CCR8 | HEK293 |
| CHO-CCR8 | INS-SF-1023 | CCR8 | CHO |
● 永生化细胞系:来自不同物种的功能性永生化细胞系。
| 品名 | 货号 | Species | Organ/Tissue |
| CI-pNaEC | INS-CI-1029 | porcine | Nasal epithel |
| CI-muMEC | INS-CI-1004 | murine | Vascular endothel |
| CI-muHepa | INS-CI-1012 | murine | Liver, hepatocytes |
| CI-muINTEPI | INS-CI-1007 | murine | Intestinal epithel (fetal) |
| CI-muADINTESTI | INS-CI-1018 | murine | Intestinal epithel (adult) |
| CI-huThyrEC | INS-CI-1017 | human | Thyroid epithel |
| CI-huVEC | INS-CI-1002 | human | Endothel, Umbilical vein |
| CI-huOB | INS-CI-1005 | human | Osteoblasts |
| CI-huMEC | INS-CI-1008 | human | Microvascular endothel |
| CI-huFIB | INS-CI-1010 | human | Fibroblasts |
| CI-huEGC | INS-CI-1030 | human | Enteric glial cells (intestine) |
| CI-huBroBEC | INS-CI-1025 | human | Lung, bronchial epithel |
| CI-hAELVi | INS-CI-1015 | human | Lung, Alveoli |
| CI-huArlo | INS-CI-1031 | human | Lung, Alveoli |
● Reagents and Consumables产品
| 分类 | 品名 | 货号 | 规格 |
| Culture Media | CHO Growth Medium A | INS-ME-1039 | 500 ml |
| Culture Media | CHO Growth Medium B | INS-ME-1040 | 500 ml |
| Culture Media | FasTEER Medium | INS-ME-1032-100 | 100 ml |
| Culture Media | HEK293 Growth Medium A | INS-ME-1041 | 500 ml |
| Culture Media | huAEC Medium | INS-ME-1013-100 | 100 ml |
| Culture Media | huAEC Medium | INS-ME-1013-500 | 500 ml |
| Culture Media | huBroBEC Medium | INS-ME-1033 | 500 ml |
| Culture Media | huEGC Medium | INS-ME-1027 | 500 ml |
| Culture Media | huFIB Medium | INS-ME-1001 | 500 ml |
| Culture Media | huMEC Medium | INS-ME-1012 | 500 ml |
| Culture Media | huOB Differentiation Medium | INS-ME-1007 | 100 ml |
| Culture Media | huOB Maintenance Medium | INS-ME-1006 | 500 ml |
| Culture Media | huThyrEC Medium | INS-ME-1017 | 500 ml |
| Culture Media | huVEC Medium | INS-ME-1011 | 500 ml |
| Culture Media | muADINTESTI Medium | INS-ME-1023 | 500 ml |
| Culture Media | muINTEPI Medium | INS-ME-1005 | 500 ml |
| Culture Media | muMEC Medium | INS-ME-1004 | 500 ml |
| Culture Media | pNaEC Medium | INS-ME-1038 | 500 ml |
| Coating Solutions | Coating Solution | INS-SU-1026 | 50ml;100ml;300ml |
| Freezing Media | Cell Freezing Medium | INS-SU-1027 | 30 ml |
▍InSCREENeX提供的服务
● Landing Pad Cells:将目标单拷贝整合到CHO、HEK293 和 Llama主细胞系中,快速生成细胞系并进行变体库整合。
● Random Integration:通过病毒或非病毒方法将目标基因随机整合到任何细胞系中。
● Cell culture services:高度定制化的细胞系服务,包括细胞库构建、细胞存储、制备:细胞沉淀(Pellets)、细胞裂解液(Lysates)、DNA、RNA、培养基优化,原代细胞分离与分选等。
● Assay services:建立并运行检测方法,包含检测方法建立与优化,代运行检测服务等。
● Molecular biology services:包含克隆构建,质粒制备,DNA/RNA分离提取与制备,慢病毒生产等服务。
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理InSCREENeX品牌全系列产品"> 艾美捷科技代理InSCREENeX品牌全系列产品
<Welligton实验室始建于1980年,致力于为客户提供高品质的标准物质,并始终站在环境科学的前沿,Wellington以矢志不渝的信念不断地推出新的合成物质,用于检测环境中不断出现的污染物。
Wellington Laboratories has been committed to providing high quality reference standards and exceptional customer service since its inception in 1980. An acute awareness of trends in the environmental community and a dedication to research and development has allowed us to synthesize a variety of emerging contaminants over the years. A few examples of The Science Behind Wellington are provided below for your review.
Wellington Laboratories的主要产品包括:
PCDD/PCDF Analytical Method Solutions
Individual PCDDs & PCDFs: Native and Mass-Labelled
Specialty Solution/Mixtures of PCDDs and PCDFs
PCB Analytical Method Solutions
Individual PCBs: Mass-Labelled
Specialty Solution/Mixtures of PCBs
Halogenated Flame Retardants & Related Compounds
Perfluorinated Compounds (PFCs)
Certified Reference Materials
Additional Products
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Wellington Laboratories"> Wellington Laboratories
艾美捷科技代理3Helix品牌胶原蛋白杂交肽(CHP)。
胶原蛋白是几乎存在于所有人体组织中,在支持细胞生长和组织形成方面发挥着重要作用。胶原蛋白受损预示着结缔组织的损伤,也是多种涉及炎症和异常组织重塑的疾病的征兆,例如癌症、
心肌梗塞、关节炎、骨质疏松症和纤维化。然而,用传统技术很难定位受损的胶原蛋白。因此,3Helix公司开发了一系列专利性的胶原蛋白杂交肽,可直接定位受损的胶原蛋白分子。
3Helix产品包括:
(1)Auto-CHP:胶原蛋白杂交肽,用于自动染色的生物素结合物;
(2)B-CHP:胶原蛋白杂交肽,生物素结合物;
(3)F-CHP:胶原蛋白杂交肽,5-FAM 结合物;
(4)In vivo:胶原蛋白杂交肽,磺基-Cy7.5 结合物 (sCy7.5-CHP);
(5)R-CHP:胶原蛋白杂交肽,Cy3 结合物。
< " data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理3Helix品牌胶原蛋白杂交肽"> 艾美捷科技代理3Helix品牌胶原蛋白杂交肽
艾美捷科技代理Rigaku Reagents品牌。
Rigaku Reagents 是 Rigaku 集团旗下的一家子公司,专注于为X射线晶体学领域提供高质量的化学试剂和工具。Rigaku 集团是全球知名的科学仪器制造商,尤其在X射线分析技术领域具有领先地位。Rigaku Reagents 的主要目标是支持科学家在蛋白质晶体学、材料科学和其他相关领域的研究,提供用于晶体生长、样品制备和分析的高质量试剂和耗材。热门产品包括:Wizard Classic/Wizard Cryo 系列蛋白结晶筛选试剂盒,结晶板,结晶工具,和 PEG3350、PEG6000、PEG8000 等试剂。主要产品类别为:
(1)晶体生长试剂:Rigaku Reagents 提供多种用于蛋白质和小分子晶体生长的试剂,包括结晶筛选试剂盒、缓冲液、沉淀剂和添加剂。这些试剂经过严格的质量控制,确保实验的可重复性和可靠性。
(2)结晶筛选试剂盒:公司提供多种结晶筛选试剂盒,如 Crystal Screen、Index Screen 和 SaltRx Screen,适用于不同类型的晶体生长实验。这些试剂盒设计科学,能够显著提高晶体生长的成功率。
(3)蛋白质结晶工具:提供用于蛋白质结晶的耗材和设备,如结晶板、密封膜和样品支架。这些工具与 Rigaku 的X射线衍射仪兼容,支持从晶体生长到数据分析的全流程。
(4)小分子结晶试剂:为小分子晶体学研究提供高质量的试剂和工具,支持药物开发、材料科学等领域的研究。
<<< " data-original="http://worthington.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Rigaku Reagents品牌"> 艾美捷科技代理Rigaku Reagents品牌
<艾美捷科技代理Aneufast品牌全系列产品
Aneufast是一家专业生产诊断非整倍体染色体试剂盒的生物公司。QF-PCR试剂盒Aneufast公司的核心产品。Aneufast™ QF-PCR试剂盒包含六组多重标记系统,基于短串联重复序列(STRs)扩增技术,可同步检测精选微卫星位点及性别决定基因(Amelogenin-SRY)。该设计通过单次反应实现多染色体同步筛查,显著提升检测效率。此标记组合可精准识别13、18、21号常染色体及X、Y性染色体的非整倍体异常。

Aneufast™ QF-PCR试剂盒具有以下特点:
● 五色荧光DNA片段分析系统:采用五重荧光标记技术,实现单次电泳中13/18/21/X/Y染色体STR标记的同步检测与区分;
● 即用型PCR预混体系:含热启动聚合酶及优化缓冲液,操作仅需 "加DNA→扩增" 两步;
● 超快速检测流程:样本到结果仅需3.5小时
● 染色体特定位点备份设计:每套试剂盒额外提供 13/18/21/X/Y染色体专属STR标记(独立分装)
● 全平台兼容性:经优化适配ABI全系列基因分析仪,如3500/3500xL Dx,SeqStudio Flex和7500 Fast Dx
● 国际质量认证:符合欧盟体外诊断指令98/79/EC;通过 ISO 9001:2000 及 ISO 13485:2003 医疗器械生产双认证
Nanostructured & Amorphous Materials, Inc.致力于纳米材料科技的应用。主要的业务包括:生产、研发、加工纳米级和非结晶材料。
Nanostructured & Amorphous Materials Inc. (NanoAmor) was founded in Los Alamos, New Mexico, USA, in September 2001. We are a leading nanomaterials company involved in all aspects of the business: manufacturing, research and development, processing, supplying and marketing of nanostructured materials and their dispersions.
Nanostructured & Amorphous Materials的主要产品包括:
Application-Oriented Carbon-Nanotubes Products
Carbon Nanotubes & Nanofibers
Carbon Nanotube Dispersions
Elements, Oxides, Carbides & Nitrides Nanoparticles
Fullerene
Graphenes, Graphene Oxides & Graphene Nanoplatelets
Graphene Film
Nanopowder Dispersions
Nanowires & Nanorods
Amorphous Ribbons
Nanocrystalline Ribbons
Amorphous & Nanocrystalline Cores
Amorphous and Nanocrystalline Magnetic Bars
Amorphous & Nanocrystalline Powders
Amorphous Brazing Foils
Superhard Materials
Surface-Modified Oxide Nanoparticles
| 品名 | 货号 | 规格 |
| CNTs Additives for Lithium-ion Battery | 1376YJ | 1kg; |
| Carbon Nanotubes Fibers | 1356YJ | meter; |
| Carbon Nanotubes Papers | 1348YJ | piece; |
| Carbon Nanotubes Films | 1350YJ | piece; |
| Carbon Nanotubes Films | 1351YJ | 咨询 |
| Water-based carbon nanotubes coatings | 1332YJ | kg; |
| Water-based carbon nanotubes coatings | 1333YJ | kg; |
| Antistatic carbon-nanotubes coatings | 1331YJA | kg; |
| Antistatic carbon-nanotubes coatings | 1331YJB | kg; |
| Conductive/heating carbon-nanotubes coatings | 1378YJA | kg; |
| 20wt% CNTs/80wt% ABS Masterbatch | 1335YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% HDPE Masterbatch | 1337YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% HIPS Masterbatch | 1338YJ | 1kg; 5kg; 10kg; |
| 25wt% CNTs/75wt% LLDPE Masterbatch | 1339YJ | 1kg; 5kg; 10kg; |
| 20wt% CNTs/80wt% PA6 Masterbatch | 1340YJ | 1kg; 5kg; 10kg; |
| 20wt% CNTs/80wt% PP Masterbatch | 1341YJ | 1kg; 5kg; 10kg; |
| 0.2 wt% SWCNTs (> 95%, D < 2 nm)/Water Dispersion | 8040YJ | 500g; |
| 0.2 wt% SWCNTs-COOH (> 95%, OD 1-2 nm)/Water Dispersion | 8042YJ | 500g; |
| 2 wt% MWCNTs (> 98%, D 5-15 nm)/Water Dispersion | 8028YJ | 500ml; |
| 2 wt% MWCNTs-COOH (> 98%, D 5-15 nm)/Water Dispersion | 8027YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/Water Dispersion | 8030YJ | 500 ml; |
| 10 wt% MWCNTs-COOH (>98%, D 30-80 nm)/Water Dispersion | 8029YJ | 500 ml; |
| 0.2 wt% SWCNTs (> 95%, D < 2 nm)/Water Paste | 8038YJ | kg; |
| 0.2 wt% SWCNTs-COOH (> 95%, OD 1-2 nm)/Water Paste | 8039YJ | 500g; kg; |
| 2 wt% MWCNTs (> 95%, D 5-15 nm)/Water Paste | 8032YJ | kg; |
| 2 wt% MWCNTs-COOH (> 95%, D 5-15 nm)/Water Paste | 8033YJ | kg; |
| 10 wt% MWCNTs (> 95%, D 30-80 nm)/Water Slurry | 8034YJ | kg; |
| 10 wt% MWCNTs-COOH (> 95%, D 30-80 nm)/Water Paste | 8035YJ | kg; |
| 12-14 wt% MWCNTs (> 95%, D 30-80 nm)/Water Paste | 8036YJ | kg; |
| 12-14 wt% MWCNTs-COOH (>95%, D 30-80 nm)/Water Paste | 8037YJ | kg; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/BA Dispersion | 8116YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/DMAC Dispersion | 8118YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/DMF Dispersion | 8115YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/IPA Dispersion | 8117YJ | 500 ml; |
| 0.2-0.3 wt% SWCNTs (> 95%, D 1-2 nm)/NMP Dispersion | 8114YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/BA Dispersion | 8124YJ | 500 ml; |
| 8-10 wt% MWCNTs (> 98%, D 30-80 nm)/BA Dispersion | 8123YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/DMAC Dispersion | 8126YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/DMAC Dispersion | 8125YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/DMF Dispersion | 8122YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/DMF Dispersion | 8121YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/IPA Dispersion | 8130YJ | 500 ml; |
| 8-10 wt% MWCNTs (> 98%, D 30-80 nm)/IPA Dispersion | 8129YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/NMP Dispersion | 8120YJ | 500 ml; |
| 5 wt% MWCNTs (> 98%, D 30-80 nm)/NMP Dispersion | 8119YJ | 500 ml; |
| 3 wt% MWCNTs (> 98%, D 5-15 nm)/PMA Dispersion | 8128YJ | 500 ml; |
| 10 wt% MWCNTs (> 98%, D 30-80 nm)/PMA Dispersion | 8127YJ | 500 ml; |
| Fullerence powder (C60, 95+%) | 8072YJ | 1g; 5g; |
| Fullerence powder (C60, 98+%) | 8073YJ | 1g; 5g; |
| Fullerence powder (C60, 99+%) | 8074YJ | 1g; 5g; |
| Fullerene powder (C60, 99.5+%) | 8075YJ | 1g; 5g; |
| Fullerene powder (C60, 99.9+%) | 8076YJ | 1g; 5g; |
| Fullerence powder (C70, 95+%) | 8077YJ | 1g; 5g; |
| Fullerence powder (C70, 98+%) | 8078YJ | 1g; 5g; |
| Fullerence powder (C70, 99+%) | 8079YJ | 1g; 5g; |
| Fullerenol Powder (hydroxylated fullerence C60) | 8080YJ | 1g; 10g; |
| Three-Dimensional Graphene (> 60 wt%, D 6-8 um, 3-4 layers) | 8109YJ | 1g; 5g; |
| 1.0-1.5 wt% Graphenes (> 98 wt%, Dia. 4-6 um, < 10 layers)/NMP paste | 8064YJ | 1g (graphene); 5g (graphene); |
| Highly Elastic Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8095YJ | 1 cylinder; 5 cylinders; |
| Ultra-light Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8093YJ | 1 cylinder; 5 cylinders; |
| Carbon Nanotubes (10 wt%) Doped Graphene Aerogel (Dia. 1.2 cm, Height 1.2 cm) | 8090YJ | 1 cylinder; 5 cylinders; |
| Carbon Nanotubes (10 wt%) Doped Graphene Aerogel (Dia. 2.0 cm, Height 2.0 cm) | 8091YJ | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (47 wt% Fe3O4, Dia. 1 cm, Height 1 cm) | 8096YJA | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (47 wt% Fe3O4, Dia. 2 cm, Height 2 cm) | 8096YJB | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (63 wt% Fe3O4, Dia. 1 cm, Height 1 cm) | 8097YJA | 1 cylinder; 5 cylinders; |
| Magnetic Graphene Aerogel (63 wt% Fe3O4, Dia. 2 cm, Height 2 cm) | 8097YJB | 1 cylinder; 5 cylinders; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam (nickel foam etched, thickness 1-1.2 mm) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| 1-3 wt% Graphene Oxide (> 98 wt%, D 1-5 um, 1-2 layers)/Water Gel, pH = 3-4 | 8047YJB34 | 1g (graphene oxide); 5g (graphene oxide); |
| Graphene Oxide Paper (Dia. 9 cm, thickness 10 um) | 8089YJ | 1 piece; 5 pieces; |
| Industrial-Grade Graphene Nanoplatelets (> 90 wt%, D 2-13 um, < 30 layers) | 8055YJ2 | 50g; 250g; 1kg; |
| 5 wt% Graphene Nanoplatelets (> 90 wt%, D 2-16 um, < 30 layers)/NMP Paste | 8059YJ | kg (paste); |
| Industrial-Grade Graphene-Nanoplatelets/Carbon-Nanotubes Composites (> 90 wt%) | 8071YJ | 50g; 100g; |
| 5 wt% (Graphene Nanoplatelets & Carbon Nanotubes)/Water Paste | 8060YJ | kg (paste); |
| 5 wt% (Graphene Nanoplatelets & Carbon Nanotubes)/NMP Paste | 8061YJ | kg (paste); |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 97% area covered | 1301YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; 10 cm x 10 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on copper substrate, > 85% area covered | 1302YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on copper substrate | 1303YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 97% area covered | 1304YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/copper substrate, > 85% area covered | 1305YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layers) graphene/copper substrate | 1306YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 97% area covered | 1307YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/singled-layered graphene/PVC substrate, > 85% area covered | 1308YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| PMMA/multi-layered (< 10 layer) graphene/PVC substrate | 1309YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 97% area covered | 1310YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on silicon-oxide substrate, > 85% area covered | 1311YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on silicon-oxide substrate | 1312YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Single-layered graphene on quartz substrate, > 97% area covered | 1313YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on quartz substrate, > 85% area covered | 1314YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on quartz substrate | 1315YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 97% area covered | 1316YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Singled-layered graphene on PET substrate, > 85% area covered | 1317YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Multi-layered (< 10 layers) graphene on PET substrate | 1318YJ | 1 cm x 1 cm; 2 cm x 2 cm; 5 cm x 5 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene Foam on Nickel Foam (thickness 1-1.2 mm) | 1319YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Graphene on PVC (nickel foam removed) | 1320YJ | 1 cm * 1 cm; 2 cm * 2 cm; 5 cm * 5 cm; 5 cm * 10 cm; |
| Silver Nanopowder (Ag, 99.9+%, 20 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7031HW | 500ml; 1L; |
| Silver Nanopowder (Ag, 99.9+%, 50 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7033HW | 500ml; |
| Silver Nanopowder (Ag, 99.9+%, 100 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7035HW | 500ml; |
| Silver Nanopowder (Ag, 99.9+%, 200 nm) 0.1 - 1 wt% Dispersion in Water with Anionic Surfactant | 7038HW | 500ml; |
| Gold Nanopowder (Au, 99.99%, 20 nm) 0.1 - 1 wt% Dispersion in Water | 7041HW | 500ml; |
| Platinum Nanopowder (Pt, 99.9+%, 20-30nm) 0.1wt% Dispersion in Water | 0488HW | 500ml; |
| Palladium Nanopowder (Pd, 99.99%, 20 nm) 0.1 - 1 wt% Dispersion in Water | 7051HW | 500ml; |
| Palladium Nanopowder (Pd, 99.9+%, 10 nm) 0.1wt% Dispersion in Water | 0466HW | kg; |
| Germanium Nanopowder (Ge, 99.9+%, 400 nm) Dispersed in 850ml of Ethanol | 0388HW | 咨询 |
| Aluminum Oxide (alpha, 20 wt%, 30-60nm) in Water | 7017WJWA | 1kg; |
| Aluminum Oxide (gamma, 20 wt%, 30 nm) in Water | 7017WJWG | 1kg; |
| Aluminum Oxide (gamma, 20 wt%, 10 nm) in water | 7016WJWG | 1kg; |
| CuO, 1 wt%, in water, APS 30 nm | 9019WJ | kg; |
| Silicon Oxide (15 wt%, 30 nm) in water | 7019WJ | 30kg; |
| Silicon Oxide (25 wt%, 30 nm) in water | 7015WJ | 1kg; |
| Silicon Oxide (25 wt%, 30 nm) in water | 7016WJ | 1kg; 10kg; |
| Titanium Oxide (Rutile, 40 wt%, 30-50 nm) in water | 7013WJWR | 1kg; |
| Titanium oxide TiO2 (40wt%, Rutile, 30-50 nm ) in Isopropanol | 5006WJ | kg; |
| Titanium Oxide (TiO2, Rutile, >99.5%, 5-30 nm,15 wt%) in water | 7012WJWR | 1kg; |
| Titanium Oxide (Anatase, 20 wt%, 5-30 nm) in IPA | 7014WJWA | 1kg; |
| Titanium Oxide (Anatase, ATO doped, 20 wt%, 15-25 nm) Slurry | 7030WJ | 5kg; |
| Titanium Oxide (Anatase, 20 wt%, 5-30 nm) in water | 7012WJWA | 1kg; |
| Titanium Oxide (Anatase, 15 wt%, 5-30 nm) in water | 7011WJWA | 1kg; |
| Titanium Oxide (TiO2, Anatase, >99.5%, 15 nm, 15 wt%) in water, negatively charged | 7011WJWANC | 咨询 |
| Titanium Oxide Nanopowder (anatase, 5 wt%, 10-20 nm) in ethanol | 7019HT | 1L; 5L; |
| Zinc Oxide (20 wt%, 40 nm) in water | 7006WJ | 1L |
| Indium Tin Oxide (ITO, 30 wt%, 20-30 nm) in Water | 7026HZW | 100g; |
| Silver nanowires (Dia. 70 - 80 nm, Length > 10 um) | 0475HW6 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver nanowires (Dia. 30 - 50 nm, Length > 10 um) | 0475HW5 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver Nanowires (Dia. 20 - 30 nm, Length > 10 um) | 0475HW4 | 1 g (silver nanowires); 5 g (silver nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW2E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW2I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 14-31 nm, L = 5-40 um, 99.95+%, 1 wt% Ag in water) | 0475NW2W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW3E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW3I | 1 g (Ag nanowires); 2 g (Ag nanowires); 3 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 25-35 nm, L = 15-25 um, 99.95+%, 1 wt% Ag in water) | 0475NW3W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW5E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW5I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 35-45 nm, L = 10-20 um, 99.95+%, 1 wt% Ag in water) | 0475NW5W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in ethanol) | 0475NW6E | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in isopropanol) | 0475NW6I | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Silver nanowires (D = 55-75 nm, L = 20-40 um, 99.95+%, 1 wt% Ag in water) | 0475NW6W | 1 g (Ag nanowires); 2 g (Ag nanowires); 5 g (Ag nanowires); 10 g (Ag nanowires); |
| Single-walled Carbon nanotubes - 60%SWNTs (90%CNTs) | 1283YJ | 1g; 5g; |
| SWNT-OH (90% CNTs, 60% SWNTs) | 1285YJF | 1g; 5g; |
| SWNT-COOH (90% CNTs, 60% SWNTs) | 1287YJF | 1g; 5g; |
| Short SWNTs (90% CNTs, 60% SWNTs) | 1281YJS | 1g; 5g; |
| SWNT-OH (> 60%, OD 1-2 nm, Length 1-3 um) | 1285YJFS | 1g; |
| SWNT-COOH (> 60%, OD 1-2 nm, Length 1-3 um) | 1287YJFS | 1g; |
| High-Purity SWNTs (> 95%, OD < 2 nm, Length 5-30 um) | 1288YJ | g; |
| Single-walled carbon nanotubes - 90%SWNTs (95%CNTs) | 1284YJ | g; 5g; |
| SWNT-OH (95% CNTs, 90% SWNTs) | 1286YJF | 1g; |
| SWNT-COOH (95% CNTs, 90% SWNTs) | 1288YJF | 1g; |
| SWCNTs (> 90%, OD 1-2 nm, Length 1-3 um) | 1246YJS | 1g; 5g; |
| Single-Walled Carbon Nanotubes (90+%), -OH Functionalized | 1586YJF | 1g; |
| Single-Walled Carbon Nanotubes (90+%), -COOH Functionalized | 1588YJF | 1g; |
| High-Purity SWNTs (> 95%, OD < 2 nm, Length 5-30 um) | 1288YJ | 1g; |
| High-Purity SWNTs, -OH functionalized (> 95%, OD 1-2 nm, Length 5-30 um) | 1368YJF | 1g; |
| High-Purity SWNTs, -COOH functionalized (> 95%, OD 1-2 nm, Length 5-30 um) | 1369YJF | 1g; |
| High-Purity Short SWNTs (> 95%, OD 1-2 nm, Length 1-3 um) | 1372YJ | 1g; |
| High-Purity Short SWNTs, -OH Functionalized (> 95%, OD 1-2 nm, Length 1-3 um) | 1373YJF | 1g; |
| High-Purity Short SWNTs, -COOH Functionalized (> 95%, OD 1-2 nm, Length 1-3 um) | 1374YJF | 1g; |
| High-Purity SWNTs (> 95%), -NH2 functionalized | 1370YJF | 1g; 5g; |
| High-Purity Short SWNTs (> 95%), -NH2 functionalized | 1371YJFS | 1g; 5g; |
| High-Purity SWNTs (> 95 %, surface area > 1,075 m2/g) | 1300YJ | 1g; |
| DWNTs (> 60%, OD 2-4 nm, Length ~50 um) | 1280YJD | 1g; 5g; 25g; |
| DWNTs-COOH (> 60%, OD 2-4 nm, Length ~50 um) | 1281YJD | g; |
| Multi-Walled Carbon Nanotube -MWNT (98%, OD 4-6 nm) | 1389YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (98%, OD 5-15 nm) | 1203YJ | 10g; 25g; |
| Multi-walled carbon nanotube -MWNT (99%, OD 5-15 nm) | 8101YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (95+%, OD 8-15 nm) | 1204YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 10-20 nm) | 1205YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 20-30 nm) | 1229YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (98+%, OD 30-50 nm) | 1231YJ | 10g; |
| Multi-wall carbon nanotube -MWNT (>98%, OD 30-80 nm) | 1233YJ | 10g; 25g; |
| Short MWNT (98+%, OD 4-6 nm, Length 0.5-2 um) | 1392YJS | 5g; |
| Short MWNT (98+%, OD 5-15 nm, Length 0.5-2 um) | 1225YJS | 5g; |
| Short MWNT (99+%, OD 5-15 nm, Length 0.5-2 um) | 8104YJS | 5g; |
| Short MWNT (95+%, OD 8-15 nm, Length 0.5-2 um) | 1235YJS | 5g; |
| Short MWNT (>98%, OD 10-20 nm, Length 0.5-2 um) | 1236YJS | 10g; |
| Short MWNT (98+%, OD 20-30 nm, Length 0.5-2 um) | 1237YJS | 5g; |
| Short MWNT (98+%, OD 30-50 nm, Length 0.5-2 um) | 1238YJS | 5g; |
| Short MWNT (98+%, OD 30-80 nm, Length 0.5-2 um) | 1227YJS | 5g; |
| Graphitized MWNT (99.9%, OD 8-15 nm) | 1219YJ | 10g; 25g; |
| Graphitized MWNT (99.9%, OD 10-20 nm) | 1220YJ | 10g; |
| Graphitized MWNT (99.9%, OD 20-30 nm) | 1221YJ | 5g; |
| Graphitized MWNT (99.9%, OD 30-50 nm) | 1222YJ | 5g; |
| Graphitized MWNT (99.9%, OD 30-80 nm) | 1223YJ | 5g; |
| Industrial-grade MWNT (95+%, OD 4-6 nm) | 1395YJ | 1kg; |
| Industrial-Grade MWNT (95+%, OD 5-15 nm) | 1201YJG | 1kg; |
| Industrial-grade MWNT (95%, OD 8-15 nm) | 1201YJA | 1kg; |
| Industrial-grade MWNT (95+%, OD 10-20 nm) | 1201YJB | 1kg; |
| Industrial-grade MWNT (95+%, OD 10-30 nm) | 1201YJC | 1kg; |
| Industrial-grade MWNT (95+%, OD 20-40 nm) | 1201YJD | 1kg; |
| Industrial-Grade MWNT (95+%, OD 30-80 nm) | 1201YJE | 1kg; |
| MWNT-OH (98+%, OD 4-6 nm) | 1390YJF | 10g; |
| MWNT-OH (98+%, OD 5-15 nm) | 1261YJF | 5g; |
| MWNT-OH (99+%, OD 5-15 nm) | 8103YJF | 5g; |
| MWNT-OH (95+%, OD 8-15 nm) | 1262YJF | 5g; |
| MWNT-OH (98+%, OD 10-20 nm) | 1263YJF | 5g; |
| MWNT-OH (98+%, OD 20-30 nm) | 1264YJF | 5g; 25g; 100g; |
| MWNT-OH (98+%, OD 30-50 nm) | 1265YJF | 5g; |
| MWNT-OH (98+%, OD 30-80 nm) | 1266YJF | 5g; |
| Short MWNT-OH (98+%, OD 4-6 nm, Length 0.5-2 um) | 1393YJF | 5 g; 100 g; |
| Short MWNT-OH (98+%, OD 5-15 nm, Length 0.5-2 um) | 1247YJF | 5g; |
| Short MWNT-OH (99+%, OD 5-15 nm, Length 0.5-2 um) | 8106YJF | 5g; |
| Short MWNT-OH (95+%, OD 8-15 nm, Length 0.5-2 um) | 1248YJF | 5g; |
| Short MWNT-OH (98+%, OD 10-20 nm, Length 0.5-2 um) | 1249YJF | 5g; |
| Short MWNT-OH (98+%, OD 20-30 nm, Length 0.5-2 um) | 1251YJF | 5g; |
| Short MWNT-OH (98+%, OD 30-50 nm, Length 0.5-2 um) | 1252YJF | 5g; |
| Short MWNT-OH (98+%, OD 30-80 nm, Length 0.5-2 um) | 1253YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 8-15 nm) | 1224YJF | 1g; |
| Graphitized MWNT-OH (99.9%, OD 10-20 nm) | 1228YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 20-30 nm) | 1235YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 30-50 nm) | 1239YJF | 1g; 5g; |
| Graphitized MWNT-OH (99.9%, OD 30-80 nm) | 1240YJF | 1g; 5g; |
| Industrial-grade MWNT-OH (95+%, OD 5-15 nm) | 1201YJI | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 8-15 nm) | 1201YJL | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 10-30 nm) | 1207YJF | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 20-40 nm) | 1208YJF | 1kg; |
| Industrial-grade MWNT-OH (95+%, OD 30-80 nm) | 1209YJF | 1kg; |
| MWNT-COOH (98+%, OD 4-6 nm) | 1391YJF | 10g; |
| MWNT-COOH (98+%, OD 5-15 nm) | 1267YJF | 5g; |
| MWNT-COOH (99+%, OD 5-15 nm) | 8102YJF | 10g; |
| MWNT-COOH (95+%, OD 8-15 nm) | 1268YJF | 5g; |
| MWNT-COOH (98+%, OD 10-20 nm) | 1269YJF | 5g; |
| MWNT-COOH (98+%, OD 20-30 nm) | 1270YJF | 5g; |
| MWNT-COOH (98+%, OD 30-50 nm) | 1271YJF | 5g; |
| MWNT-COOH (98+%, OD 30-80 nm) | 1272YJF | 5g; |
| Short MWNT-COOH (98+%, OD 4-6 nm, Length 0.5-2 um) | 1394YJF | 5g; |
| Short MWNT-COOH (98+%, OD 5-15 nm, Length 0.5-2 um) | 1254YJF | 5g; |
| Short MWNT-COOH (99+%, OD 5-15 nm, Length 0.5-2 um) | 8105YJF | 5g; |
| Short MWNT-COOH (95+%, OD 8-15 nm, Length 0.5-2 um) | 1255YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 10-20 nm, Length 0.5-2 um) | 1256YJF | 5g; |
| Short MWNT-COOH (98+%, OD 20-30 nm, Length 0.5-2 um) | 1257YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 30-50 nm, Length 0.5-2 um) | 1259YJF | 1g; 5g; |
| Short MWNT-COOH (98+%, OD 30-80 nm, Length 0.5-2 um) | 1273YJF | 1g; 5g; |
| Graphitized MWNT-COOH (99.9%, OD 8-15 nm) | 1241YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 10-20 nm) | 1242YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 20-30 nm) | 1243YJF | 10g; |
| Graphitized MWNT-COOH (99.9%, OD 30-50 nm) | 1244YJF | 1g; 5g; |
| Graphitized MWNT-COOH (99.9%, OD 30-80 nm) | 1245YJF | 1g; 5g; |
| Industrial-grade MWNT-COOH (95+%, OD 5-15 nm) | 1201YJH | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 8-15 nm) | 1201YJK | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 10-30 nm) | 1210YJF | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 20-40 nm) | 1216YJF | 1kg; |
| Industrial-grade MWNT-COOH (95+%, OD 30-80 nm) | 1218YJF | 1kg; |
| Aligned MWNT (98+%, OD 8-15 nm, Length: 30-50 um) | 1215YJA | 25g; |
| Carbon nanofibers (70+%, D = 200-600 nm, L = 5-50 um) | 1177YJ | 10g; |
| Carbon Nanofibers (95+%, D = 50-200 nm, L = 1-15 um) | 8107YJ | 10g; |
| Graphitized carbon nanofibers (95+%, OD = 50-200 nm, L = 1-15 um) | 1178YJ | 10g; |
| Graphene (> 98 wt%, D > 50 um, < 3 layers) | 2191YJ | 1g; 5g; |
| Graphene Oxide (> 99 wt%, D 0.5-3 um, < 3 Layers) | 2192YJ | 1g; 5g; |
| Graphene Nanoplatelets (> 99.5 wt%, D 5-10 um, < 20 layers) | 8056YJ | 1g; 5g; 25g; |
| Industrial-Grade Graphene Nanoplatelets (> 90 wt%, D 2-16 um, < 30 layers) | 8055YJ | 50g; 250g; 1kg; |
| *60% Ni/38% MWNT (95+%, OD 8-15 nm) | 1293YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 10-20 nm) | 1294YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 20-30 nm) | 1295YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 30-50 nm) | 1296YJ | 10g; |
| *60% Ni/38% MWNT (95+%, OD 30-80 nm) | 1297YJ | 10g; |
| MWNT-NH2 (95+%, OD 8-15 nm, 0.45 wt% amino) | 1562YJF | 5g; |
| Nitrogen-doped MWNTs (98%, OD 30-80 nm) | 8054YJ | 5g; |
| Large inner diameter thin-walled multi-walled carbon nanotubes | 1563YJF | 5g; |
| Coiled CNTs (60+%, OD 100-200 nm, Length 1-10 um) | 1298YJ | 5g; |
| Silver Nanopowder (Ag, 99.99%, 400 nm ) | 0487HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 200 nm ) | 0479HW | 咨询 |
| Silver Nanopowder (Ag, 99.99%, 100 nm ) | 0489HW | 咨询 |
| Silver Nanopowder (Ag, 99%, 90-210 nm) | 0471CD | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 80 nm ) | 0475HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 80 nm, w/~0.3% PVP ) | 0476HW | 咨询 |
| Silver Nanopowder (Ag, 99.9% , 40 nm ) | 0473HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 40 nm, w/~0.3% PVP ) | 0474HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 30-50 nm, w/0.2 wt% PVP) | 0477YD | 咨询 |
| Silver Nanopowder (Ag, 35 nm, 99.5%, metal basis) | 0476JY | 咨询 |
| Silver Nanopowder (Ag, 99.9% , 20 nm ) | 0477HW | 咨询 |
| Silver Nanopowder (Ag, 99.9%, 20 nm, w/~0.3% PVP ) | 0478HW | 咨询 |
| Aluminum Powder (99.9%, 500 um) | 0156HW | 咨询 |
| Aluminum Powder (99.9%, 50 um) | 0154HW | 咨询 |
| Aluminum Powder (99.9%, 5 um) | 0152HW | 咨询 |
| Aluminum Nanoparticles (99.9%, 500 nm) | 0150HW | 咨询 |
| Aluminum Nanopowder (Al, 99.9+%, 70-80 nm) | 0137HW | 咨询 |
| Aluminum Nanopowder (99.9+%, 70-80 nm, w/PVP) | 0140HW | 咨询 |
| Aluminum Nanopowder (Al, 99.9+%, 40-50 nm) | 0138HW | 咨询 |
| Aluminum Nanopowder (99.9+%, 40-50 nm, w/PVP) | 0139HW | 咨询 |
| Aluminum Nanopowder (Al, 99+%, metal basis, 18 nm) | 0136JY | 咨询 |
| Gold (Au) Nanopowder (99.9%, 50-100 nm) | 0795CD | 咨询 |
| Gold (Au) Nanopowder (25nm, 99.9%) | 8801HW | 咨询 |
| Gold (Au) Nanopowder (10-20 nm, 99.95%) | 8796HW | 咨询 |
| Gold (Au) Nanopowder (10nm, 99.9%) | 8799HW | 咨询 |
| Bismuth Nanopowder (Bi, 99.9%, 80-100 nm) | 0832HW | 咨询 |
| Bismuth Nanopowder (Bi, 99.5%, 40-60 nm) | 0831HW | 咨询 |
| Nano Activated Carbon (C, 88+%, 100 nm) | 1211NH | 咨询 |
| Diamond Nanopowder (synthesized, 55-70%, 4-15nm) | 1311JGY | 咨询 |
| Diamond Nanopowder (synthesized, 98+%, 3-10 nm) | 1321JGY | 咨询 |
| Diamond Nanopowder (synthesized, 97%, 3-6 nm) | 1350SL | 咨询 |
| Graphite Nanopowder (400 nm, 99.9%) | 1250HT | 咨询 |
| *Cobalt Nanopowder, Carbon Coated (Co, 99%, 40 nm) | 0286HW | 咨询 |
| *Cobalt Nanopowder (Passivated, 99.8%, 28 nm) | 0276JY | 咨询 |
| *Chromium Nanopowder (Cr, 99.5%, 50 nm) | 0240XX | 咨询 |
| *Copper Nanopowder (Cu, 99%, 500 nm) | 0293HW | 100g; |
| *Copper Nanopowder (Cu, 99.9%, 200 nm) | 0290HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 100 nm) | 0298HW | 25g; |
| *Copper Nanopowder (Partially Passivated, 99+%, 80 nm) | 0294HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 70 nm) | 0291HW | 25g; |
| *Copper Nanopowder (Cu, 99.5%, 50-80 nm) | 0292HW | 25g; |
| *Copper Nanopowder (Cu, 99.9%, 40 nm) | 0295HW | 25g; |
| *Copper Nanopowder (Cu, carbon coated, 99.8%, 25 nm) | 0297JY | 5g; |
| *Iron Nanopowder (Fe, 99.9%, 500nm) | 0272YM | 100g; 1kg; |
| *Iron Nanopowder (Fe, 99.9%, 100 nm) | 0264HW | 25g; |
| *Iron Nanopowder (Fe, 99.9%, 70 nm) | 0263HW | 25g; 100g; |
| *Iron Nanopowder (Fe, 99.9%, 40 nm) | 0262HW | 25g; 100g; |
| *Iron nanopowder, carbon coated (Fe/C, 99.6%, 25 nm) | 0267JY | 25g; |
| Germanium Nanopowder (Ge, 99.9+%, 600 nm) | 0327HW | 25g; |
| Germanium Nanopowder (Ge, 99.9%, 500 nm) | 0331HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 400 nm) | 0326HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 300 nm) | 0325HW | 1kg; |
| Germanium Nanopowder (Ge, 99.9+%, 200 nm) | 0323HW | 100g; kg; |
| Germanium Nanopowder (Ge, 99.9+%, 150 nm) | 0322HW | 咨询 |
| Germanium Nanopowder (Ge, 99.9+%, < 100 nm) | 0322HH | 咨询 |
| Germanium Nanopowder (Ge, 99.9+%, 20-50 nm) | 0321HW | 5g; |
| Iridium Nanopowder (Ir, 99.95%, 20-30 nm), wet powder in Deionized Water | 0771HW | 咨询 |
| *Molybdenum Nanopowder (Mo, 99.5%, 70 nm) | 0423HW | 咨询 |
| Niobium Nanopowder (Nb, 99.9%, 40-60 nm) | 0411HW | 咨询 |
| *Nickel Nanopowder (Ni, 99%, 800 nm) | 0302HW | 咨询 |
| *Nickel Nanopowder (Ni, 99%, 400 nm) | 0301HW | 100g; 1kg; |
| *Nickel Nanopowder (Ni, 99+%, 300 nm) | 0289HW | 1kg; |
| *Nickel Nanopowder (Ni, 99.5%, 100 nm) | 0285HW | 25g; |
| *Nickel Nanopowder (Ni, 99.9%, 80 nm) | 0284HW | 300g; |
| *Nickel Nanopowder (Ni, 99.5%, 70 nm) | 0288HW | 25g; |
| *Nickel Nanopowder (Ni, 99.5%, 40 nm) | 0283HW | 25g; |
| *Nickel Nanopowder, carbon coated (Ni/C, 99.9%, 20 nm) | 0287JY | 5g; |
| Palladium Nanopowder (Pd, 99.95%, 20-30 nm) | 0462HW | 咨询 |
| Platinum Nanopowder (Pt, 99.95%, 20-30 nm) | 0782HW | 咨询 |
| Platinum Nanopowder, PVP coated (Pt, 99.95%, 20-30 nm) | 0787HW | 1g; |
| Platinum Nanopowder (Pt, 99.9%, 20-30 nm) | 0786HW | 1g; 5g; |
| Rhodium Nanopowder (Rh, 99.95%, 20-30 nm) | 0451HW | 咨询 |
| Ruthenium Nanopowder (Ru, 99.95%, 20-30 nm) | 0441HW | 1g; |
| *Silicon Nanopowder (Si, 99%, 400 nm) | 0144HW | 100g; |
| *Silicon Nanopowder (Si, 99.9%, 100 nm) | 0149HW | 100g; |
| *Silicon Nanopowder (Si, > 97%, 50 nm) | 0145KE | 咨询 |
| *Silicon Nanopowder (Si, 99%, 30-50 nm) | 0147HW | 50g; |
| *Silicon Nanopowder (Si, 98+%, 30-50 nm) | 0141JS | 50g; 100g; 500g; 1kg; |
| Tin Nanopowder (Sn, 70 nm, w/PVP ) | 5522HW | 500g; |
| Tin Nanopowder (Sn, 99.9%, 60-80 nm) | 0501HW | 咨询 |
| *Tantalum Nanopowder (Ta, 99.9%, 40 nm) | 0225HW | 25g; |
| *Tantalum Nanopowder (Ta, 99.9%, 70 nm) | 0224HW | 25g; |
| *Titanium Nanopowder (Ti, 99%, 60-80 nm) | 0227HW | 25g / $361; |
| *Tungsten Powder (W, 99.5+%, 1-2 um) | 0747HW | 100g; |
| *Tungsten Nanopowder (W, 99.5%, 500 nm) | 0749HW | 1kg; |
| *Tungsten Nanopowder (W, 99.5%, <100 nm) | 0745HW | 100g; |
| *Zinc Nanopowder (Zn, 99%, 500 nm) | 0318HW | 1kg; |
| *Zinc Nanopowder (Zn, 99.5%, 130 nm) | 0303HW | 25g; |
| *Zinc Nanopowder (Zn, 99.9+%, 100 nm) | 0306JY | 25g; |
| *Zinc Nanopowder (Zn, 99.5%, 80 nm) | 0304HW | 25g; |
| *Aluminum Nitride Nanopowder (AlN, Amorphous, <0.5um, 99.9%) | 1004HW | 咨询 |
| Aluminum Nitride Nanopowder (AlN, 99.9 %, 0.5 um) | 1005HW | 咨询 |
| *Aluminum Nitride Nanopowder (AlN, 99.5 %, 70-80 nm) | 1002HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 500 μm) | 1175HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 50 μm) | 1177HW | 咨询 |
| Boron Carbide Powder (B4C, 99%, 40 μm) | 1179HW | 1kg; |
| Boron Carbide Powder (B4C, 98%, 20μm) | 1172HW | 1kg; |
| Boron Carbide Powder (B4C, 98%, 10μm) | 1169HW | 1kg; |
| Boron Carbide Powder (B4C, 99%, 5 μm) | 1165HW | 1kg; |
| Boron Carbide Powder (B4C, 99%, 2 um) | 1183HW | 1 kg; |
| Boron Carbide Powder (B4C, 99+%, 1-2 μm) | 1162HW | 咨询 |
| Boron Carbide Nanopowder (B4C, 99+%, 500 nm) | 1160HW | 500g; |
| Boron Carbide Nanopowder (B4C, 99%, 50nm) | 1161HY | 100g; |
| Boron Nitride Powder (BN, hexagonal, 99.8%, 0.6-1.2um) | 1182HW | 咨询 |
| Boron Nitride Nanopowder (BN, hexagonal, 99%, 137 nm) | 1180YL | 25g; |
| Boron Nitride Nanoplates (BN, 99.5+%, 100 nm) | 1183NJ | 100g; |
| Chromium Carbide Nanopowder (Cr3C2, 99.9%, <100 nm) | 0247HW | 500g; 1kg; |
| Hafnium Boride Nanopowder (HfB2, 99+%, 60 nm) | 1010JC | 100g; |
| Hafnium Carbide Nanopowder (HfC, 99+%, 200 nm) | 1005JC | 500g; |
| Hafnium Carbide Nanopowder (HfC, 99+%, 60 nm) | 1006JC | 100g; |
| Hafnium Carbide Nanopowder (HfC, 99%, 50nm) | 1022JC | kg; |
| Niobium Carbide Nanopowder (NbC, 99.9%, 500 nm) | 3860YM | 咨询 |
| Silicon Carbide Powder (SiC, 500 um, 99%, Hexagonal) | 4652HW | 1kg; ; |
| Silicon Carbide Powder (SiC, 50 um, 99%, Hexagonal) | 4654HW | 1kg; ; |
| Silicon Carbide Micron Powder (SiC, Beta, 40um, 99+%) | 4645HW | 1kg; ; |
| Silicon Carbide Powder (SiC, Beta, 20um, 99+%) | 4643HW | 1kg; ; |
| Silicon Carbide Powder (SiC, Beta, 10um, 99+%) | 4641HW | 1kg; ; |
| Silicon Carbide Micron Powder (SiC, Beta, 7um, 99+%) | 4639HW | 100g; 1kg; ; |
| Silicon Carbide Powder (SiC, beta, 99.8%, 5 μm) | 4637HW | 100g; ; |
| Silicon Carbide Powder (SiC, beta, 99+%, 2 μm) | 4635HW | 咨询 |
| Silicon Carbide Powder (SiC, alpha, 99.9%, 2um) | 4627HY | 1kg; |
| Silicon Carbide Powder (SiC, 500 nm, 99%, Cubic) | 4656HW | 1kg; ; |
| Silicon Carbide Nanopowder (SiC, beta, 99%, 80-100 nm) | Stock # 4629HW | 100g; |
| Silicon Carbide Nanopowder (SiC, alpha, 99.9%, 55 nm) | 4625HY | 100g; |
| Silicon Carbide Nanopowder (SiC, beta, 97.5%, 45-55 nm) | 4620KE | 200g; |
| Silicon Carbide Nanopowder (SiC, alpha, 99.9%, 30 nm) | 4626HY | 100 g; 150 g; |
| Silicon Carbide Nanowhisker (beta, SiC, 99+%) | 4622HW | 25g; |
| Silicon Nitride Nanopowder (Si3N4, amorphous, 98.5+%, 15-30 nm) | 4750KE | 100g; |
| Titanium Boride Powder (TiB2, 2-12 μm ) | 5180HW | 100g |
| *Titanium Carbide Powder (TiC, 1 micron, 99%) | 5218YL | 500g; |
| *Titanium Carbide Nanoparticles (TiC, 100-200nm, 99+%) | 5217HW | 1kg; |
| Titanium Carbide (TiC, 99+%, 100 nm) | 5217JC | 100g; |
| *Titanium Carbide (TiC, 98+%, 80 nm) | 5220HT | 25g; 100g; |
| *Titanium Carbide Nanopowder (TiC, 97+%, 50 nm) | 5216KE | 100g; |
| *Titanium Nitride Powder (TiN, 99%, 1-3um) | 5352JC | 500g; 1kg; |
| *Titanium Nitride Nanoparticles (TiN, 99%, 100-200 nm) | 5357HW | 500g; |
| *Titanium Nitride Nanopowder (TiN, 97+%, 20 nm) | 5350KE | 100g; |
| Tungsten Carbide/Cobalt Nanopowder (8wt%Co/WC, < 200 nm, 99.5%) | 5561HW | 100g |
| Zirconium Carbide Nanopowder (ZrC, 99%, 8 um) | 5905KE | 100g; 250g; 500g; |
| *Zirconium Carbide Nanopowder (ZrC, 97%, 60 nm) | 5901KE | 100g; |
| *Zirconium Nitride Nanopowder (ZrN, 99.5%, 1-3um) | 6101JC | 500g; kg; |
| Zirconium Boride Nanopowder (ZrB2, 99%, 60 nm) | 5950JC | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9+%, 500 nm) | 1037HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99+%, 500 nm) | 1038HT | 100g; |
| Aluminum Oxide Nanopowder (alpha, aluminate coated, 98+%, 500 nm) | 1039HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9%, 200 nm) | Stock #:1040LQS | 100g |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9%, 150 nm) | 1005MR | 100g ; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha, 99.9+%, 40-50 nm) | 1044HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (alpha/theta, 99.99%, ~30nm ) | 1018WJ | 100g ; |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99+%, 500 nm) | 1045HT | 100g; |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99.97%, 20-30 nm) | 1020MR | 100g; 500g; 1kg; |
| Aluminum Oxide Nanopowder (gamma, 99.5%, 50 nm) | 1007XX | 咨询 |
| Aluminum Oxide (Al2O3) Nanopowder (gamma, 99.99%, 10 nm) | 1043HT | 100g; |
| Aluminum oxide nanopowder, (γ-phase) APS 20-30 nm, 99.95+% | 0125HW | 咨询 |
| Aluminum Oxide Nanopowder ( 99.99%, 30 nm ) for Lithium Batteries | 1016WJ | 咨询 |
| Aluminum Hydroxide Nanopowder (99.5 %, 50 nm) | 1040WJ | 咨询 |
| Boron Oxide Nanopowder (B2O3, 98%, 40-80 nm) | 1185DF | 咨询 |
| Boron Oxide Nanopowder (B2O3, 99%, 40-80 nm) | 1186DF | 1kg; |
| Bismuth Oxide Nanopowder (Bi2O3 , 99.9%, 100 nm) | 1171HT | kg; |
| Cerium Oxide, (CeO2, 99.99%, 200 nm) | 1445MG | 100g; |
| Cerium Oxide Nanopowder (CeO2, 99%, 50-100 nm) | 1408HW | 100g; |
| Cerium Oxide (CeO2, 99.99%, 20-30 nm) | 1444ZQ | 100g; |
| Cerium Oxide Nanopowder (CeO2, 99.9%, 15-30 nm) | 1406RE | 100g; |
| Cobalt(II,III) Oxide Nanopowder (Co3O4, 99%, 50-80 nm) | 1720HT | 咨询 |
| Chromium Oxide Powder (Cr2O3, 99.8%, 1 um) | 1920FY | 25g; 1kg; |
| Chromium Oxide Powder (Cr2O3, 99.9%, 100 nm) | 1925FY | 100g; 1kg; |
| Chromium Oxide Nanopowder (Cr2O3, 99+%, 60 nm) | 1910FY | 25g; |
| Copper(II) Oxide Nanopowder (CuO, 99+%, 30-50 nm) | 2110FY | 咨询 |
| Copper(I) Oxide Nanopowder (Cu2O, 99%, 30-50 nm) | 2113HW | 25g; 100g; 500g; 1kg; |
| Dysprosium Oxide Nanopowder (Dy2O3, 99.9%, 55 nm) | 2252YS | 25g; |
| Dysprosium Oxide Nanopowder (Dy2O3, 99.9%, 30-70 nm) | 2253ZQ | 25g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 43 nm) | 2310ZQ | 65g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 41-53 nm) | 2350YS | 25g; |
| Erbium Oxide Nanopowder (Er2O3, 99.9%, 20-30 nm) | 2330RE | 25g ; |
| Europium Oxide Nanopowder (Eu2O3, 99.995%, 58 nm) | 2410ZQ | 5g; |
| Europium Oxide Nanopowder (Eu2O3, 99.99%, 45-58 nm) | 2450YS | 5g; |
| Europium Oxide Nanopowder (Eu2O3, 99.99%, 30-50 nm) | 2411RE | 5g; |
| Iron(III) Oxide Nanopowder (Fe2O3, gamma, 99.98%, 50 nm) | 2527YM | 1kg |
| Iron(III) Oxide Nanopowder (Fe2O3, alpha, 99%, 30-50 nm) | 2520ZH | 25g; 100g; |
| Iron(III) Oxide Nanopowder (Fe2O3, alpha, 99%, 30 nm) | 2525WJ | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, 100-200 nm) | 2653HW | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 97%, 50-100 nm) | 2650TS | 100g; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, SSA: 9-14 m2/g, 50-100 nm) | 2655HW | 100g; 500g; 1kg; |
| Iron(II,III) Oxide Nanopowder (Fe3O4, 99%, 30 nm) | 2651WJ | 100g; |
| Iron Oxide Nanopowder (Fe3O4, PVP coated, 99+%, 20-30 nm) | 2657HW | 100g; 1kg; |
| Gadolinium Oxide Nanopowder (Gd2O3, 99.9+%, 20-80 nm) | 2680ZQ | 咨询 |
| Gadolinium Oxide Nanopowder (Gd2O3, 99.9%, 15-30 nm) | 2681RE | 咨询 |
| Hafnium Oxide Powder (HfO2, 99.99%, 48um) | 1045HW | 咨询 |
| Hafnium Oxide Powder (HfO2, 99%, 45um) | 1042HW | 咨询 |
| Indium Oxide Nanopowder (In2O3, 99.99%, 100-200 nm) | 2711TN | 咨询 |
| Indium Hydroxide Nanopowder (In(OH)3, 99.99%, 20-70 nm) | 2810TN | 咨询 |
| Lanthanum Oxide Nanopowder (La2O3, 99%, 50 nm) | 2922RE | 咨询 |
| Lanthanum Oxide Nanopowder (La2O3, 99.99%, 15-30 nm) | 2920RE | 咨询 |
| Magnesium Oxide Nanopowder (MgO, 99+%, 40-60 nm) | 3305HT | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 40nm) | 3912RE | 1kg; |
| Magnesium Oxide Nanopowder (MgO, 99+%, 40 nm) | 3304HT | 咨询 |
| Magnesium Hydroxide Nanopowder (Mg(OH)2, 98+%, 100 nm) | 3321HT | 咨询 |
| Molybdenum(VI) Oxide Nanopowder (MoO3 , 99.5%, 100 nm) | 3851XW | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9+%, 83 nm) | 3910ZQ | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 49-64 nm) | 3950YS | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 40nm) | 3912RE | 咨询 |
| Neodymium Oxide Nanopowder (Nd2O3, 99.9%, 15-30 nm) | 3911RE | 25g; |
| Nickel Oxide Nanopowder (Ni2O3, 99.9%, 20-30 nm) | 4216HW | 100g; |
| Praseodymium Oxide Nanopowder (Pr6O11, 99.9%, 15-30 nm) | 4451RE | 25g; |
| Antimony Oxide Nanoparticles (Sb2O3, 99.99%, 20-30nm) | 6850HW | 咨询 |
| Silicon Oxide Powder (SiO2 , quartz, 99.99%, 1-3.5 μm) | 4856WG | 咨询 |
| Silicon Oxide Powder (SiO2 , quartz, 99.998%, 1-3.5um) | 4855WG | 咨询 |
| Silicon Oxide Nanopowder (SiO2 , 99+%, 20 nm) | 4830HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4831HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4832HT | 咨询 |
| Silicon Oxide Nanopowder (99+%, 20 nm, hydrophilic & lipophilic) | 4833HT | 咨询 |
| Samarium Oxide Nanopowder (Sm2O3, 99.9%, 42-55 nm) | 4950YS | 咨询 |
| Samarium Oxide Nanopowder (Sm2O3, 99.9%, 15-30 nm) | 4951RE | 咨询 |
| Titanium Oxide Nanopowder (TiO2, amorphous/anatase, 99+%, 5 nm) | 5416HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 99%, 10-30 nm) | 5420HT | 咨询 |
| Titanium Oxide Nanopowder(TiO2, anatase, 99%,15 nm) | 5430MR | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 99+%, 10 nm) | 5417HT | 咨询 |
| Titanium Oxide Nanopowder (tungsten oxide doped, TiO2/WO3, anatase, 10 nm) | 5418HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase, 5 nm) | 5421ZH | 咨询 |
| Titanium Oxide Nanotubes (TiO2, anatase, 99%, 10-15 nm) | 5432HW | 咨询 |
| Titanium Oxide Nanopowder (TiO2, anatase/rutile, 99+%, 20 nm) | 5419HT | 咨询 |
| Titanium oxide, silica & alumina coated (anatase/rutile, 30 nm) | 5426HT | 咨询 |
| Titanium oxide (silica, alumina & stearic acid coated, anatase/rutile, 30 nm) | 5427HT | 咨询 |
| Titanium Oxide Nanopowder (silica, alumina & silicone oil coated, anatase/rutile, 30 nm) | 5428HT | 咨询 |
| Titanium oxide, silica coated (anatase/rutile, 20 nm) | 5422HT | 咨询 |
| Titanium oxide, silica & alumina coated (anatase/rutile, 20 nm) | 5423HT | 咨询 |
| Titanium oxide, silica & stearic acid coated (anatase/rutile, 20 nm) | 5424HT | 咨询 |
| Titanium oxide, silica & silicone oil coated (anatase/rutile, 20 nm) | 5425HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 500 nm) | 5429HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 150 nm) | 5430HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.9+%, 100 nm) | 5431HT | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.8%, 60 nm) | 5486WJ | 咨询 |
| Titanium Oxide Nanopowder (TiO2, rutile, 99.8%, 20-50 nm) | 5484WJ | 咨询 |
| Titanium Oxide (TiO2, rutile, coated with silicon oxide, 20 nm) | 0302HT | 咨询 |
| Titanium Oxide (TiO2, rutile, coated with silicon oxide, 20 nm) | 0301HT | 咨询 |
| Vanadium Oxide Nanopowder (VO2, 99.9+%, 100 - 200 nm) | 5495HW | 咨询 |
| 1.5% Tungsten-doped Vanadium Oxide Nanopowder (W-doped VO2, 99.9+%, 30 - 50 nm) | 5499HW | 咨询 |
| 1% Tungsten-doped Vanadium Oxide Nanopowder (W-doped VO2, 99.9+%, 30 - 50 nm) | 5498HW | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99.5%, 60-120 nm) | 5508YL | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99.9+%, 40-50 nm) | 5506BD | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99+%, 30-70 nm) | 5505YL | 咨询 |
| Tungsten Oxide Nanopowder (WO3, 99+%, 30-70 nm, PVP-coated) | 5506YL | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.995%, 50-70 nm) | 5610ZQ | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.99%, 20-40 nm) | 5611RE | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.9%, 32-36 nm) | 5650YS | 咨询 |
| Yttrium Oxide Nanopowder (Y2O3, 99.995%, 20-40 nm) | 5611ZQ | 咨询 |
| Ytterbium Oxide Nanopowder (Yb2O3, 10-80 nm, 99.9%) | 5671RE | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99+%, 800 nm) | 5816HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99%, 30 nm) | 5811HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, hydrophilic & lipophilic) | 5812HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, silicone oil coated) | 5814HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 98+%, 30 nm, stearic acid coated) | 5815HT | 咨询 |
| Zinc Oxide Nanopowder (ZnO, 99%, 20 nm) | 5810HT | 咨询 |
| Zirconium Oxide Nanopowder (ZrO2, 99+%, 50 nm) | 5936HT | 咨询 |
| Zirconium Oxide Nanopowder (ZrO2, 99.5+%, 20 nm) | 5931HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/3 mol% Y2O3, 99.5+%, 15-50 nm) | 5932HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/5 mol% Y2O3, 99.5+%, 15-50 nm) | 5934HT | 咨询 |
| Zirconia Nanopowder, Yttria Doped (ZrO2/8 mol% Y2O3, 99.5+%, 15-50 nm) | 5933HT | 咨询 |
| Zirconia Nanopowder, Calcia Doped (ZrO2/8 mol%CaO, 99.9%, 20-30 nm) | 5934ZS | 咨询 |
| Barium Titanate Nanopowder (BaTiO3 , 99.9%, 400 nm) | 1146DY | 100g; |
| Barium Titanate Nanopowder (BaTiO3 , 99.9%, 300 nm) | 1144DY | 咨询 |
| Barium Titanate Nanopowder (BaTiO3 , 99.5%, 100-200 nm) | 1148DY | 咨询 |
| Cobalt Iron Oxides Nanopowder (CoFe2O4, 98%, 35-55 nm) | 1510FY | 25g ; 100g; |
| Cobalt-Zinc Iron Oxide Nanopowder (Co0.5Zn0.5Fe2O4, 99.5%, 30-50 nm) | 1515FY | 25g ; 100g; |
| Indium Tin Oxide Nanopowder (In2O3:SnO2 = 90wt%:10wt%, 99.99%, 20-70 nm) | 2730TN | 5g; 25g; |
| Indium Tin Oxide Nanopowder (In2O3:SnO2 = 95 wt%:5 wt%, 99.99%, 30-50 nm) | 2731BY | 5g; 25g; |
| Nickel-Zinc Iron Oxide Nanopowder (Ni0.5Zn0.5Fe2O4, 98.5%, 10-30 nm) | 4115FY | 100g; 500g; |
| *Ni80Fe17Mo3 permalloy nanopowder (99+%, 70 nm) | 9288HW | 100g; |
| Yttrium Aluminate w/Nd doped (Y2.98Nd0.02Al5O12, Nd-YAG, 99.5%, 40 nm) | 5571FY | 25g; 100g; |
| Zinc Iron Oxide Nanopowder (ZnFe2O4, 98.5%, 40 nm) | 5710FY | 100g; |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司,致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员,Helvetica Health Care通过了ISO 13485认证,在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板,适用于不同的分子测试平台和检测。这些产品有多种规格,可用于单一或多种分析物的检测,帮助实验室监控测试性能,确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制,满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖:抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。

▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:18771997407
邮箱:sales@amyjet.com
0.2402